Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CELG
- CUSIP: 15102010
- Web: www.celgene.com
- Market Cap: $107.56 billion
- Outstanding Shares: 780,824,000
- 50 Day Moving Avg: $128.98
- 200 Day Moving Avg: $122.58
- 52 Week Range: $96.93 - $138.93
Sales & Book Value:
- Trailing P/E Ratio: 51.24
- Foreward P/E Ratio: 15.62
- P/E Growth: 0.91
- Annual Revenue: $11.68 billion
- Price / Sales: 9.21
- Book Value: $9.79 per share
- Price / Book: 14.07
- EBIDTA: $4.11 billion
- Net Margins: 18.32%
- Return on Equity: 70.94%
- Return on Assets: 16.37%
- Debt-to-Equity Ratio: 1.80%
- Current Ratio: 4.42%
- Quick Ratio: 4.23%
- Average Volume: 3.98 million shs.
- Beta: 1.89
- Short Ratio: 2.24
Frequently Asked Questions for Celgene Corporation (NASDAQ:CELG)
What is Celgene Corporation's stock symbol?
Celgene Corporation trades on the NASDAQ under the ticker symbol "CELG."
When did Celgene Corporation's stock split? How did Celgene Corporation's stock split work?
Celgene Corporation's stock split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene Corporation stock prior to the split would have 200 shares after the split.
How were Celgene Corporation's earnings last quarter?
Celgene Corporation (NASDAQ:CELG) announced its quarterly earnings data on Thursday, April, 27th. The company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.21. The business earned $2.96 billion during the quarter, compared to the consensus estimate of $3.04 billion. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The company's revenue was up 17.8% on a year-over-year basis. During the same period last year, the business earned $1.32 earnings per share. View Celgene Corporation's Earnings History.
When will Celgene Corporation make its next earnings announcement?
What guidance has Celgene Corporation issued on next quarter's earnings?
Celgene Corporation updated its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of $7.15-7.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.21. The company issued revenue guidance of $13.0-13.4 billion, compared to the consensus revenue estimate of $13.26 billion.
Where is Celgene Corporation's stock going? Where will Celgene Corporation's stock price be in 2017?
26 equities research analysts have issued 1-year price targets for Celgene Corporation's stock. Their predictions range from $98.00 to $162.00. On average, they expect Celgene Corporation's stock price to reach $141.27 in the next twelve months. View Analyst Ratings for Celgene Corporation.
What are analysts saying about Celgene Corporation stock?
Here are some recent quotes from research analysts about Celgene Corporation stock:
- 1. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration. Celgene continues to progress with its label expansion efforts and pipeline development. Revlimid was approved as a single agent for maintenance therapy in adult patients with NDMM following ASCT both in the U.S. and EU. Celgene’s NDA for Idhifa for relapsed and/or refractory acute myeloid leukemia was granted Priority Review with a PDUFA action date of Aug 30, 2017. Label expansion of drugs would boost revenues significantly. Moreover, shares of Celgene have outperformed the industry in the past one year. However, Celgene is highly dependent on Revlimid. Otezla sales in the first quarter were impacted by managed care dynamics that drove lower total marketplace prescriptions for psoriasis therapies although the pressure should ease as the year goes." (7/19/2017)
- 2. Cantor Fitzgerald analysts commented, "Acquisition of worldwide Rights to BeiGene,s (NASDAQ: BGNE, NC) excluding Asia, PD-1 inhibitor for solid tumors, BGB-A317, enhances CELG’s oncology portfolio and augments its immuno-oncology efforts." (7/6/2017)
- 3. Cann analysts commented, "The 2017 American Society of Clinical Oncology Meeting provided a venue for data presentations for a number of Celgene’s partnered programs, including enasidenib, BMCA CAR-T and JARCAR 017. Celgene had data on its wholly owned products, Revlimid and Abraxane." (6/7/2017)
Who are some of Celgene Corporation's key competitors?
Some companies that are related to Celgene Corporation include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), BeiGene (BGNE), Agios Pharmaceuticals (AGIO) and China Biologic Products (CBPO).
Who are Celgene Corporation's key executives?
Celgene Corporation's management team includes the folowing people:
- Robert J. Hugin, Executive Chairman of the Board
- Scott A. Smith, President, Chief Operating Officer
- Mark J. Alles, Chief Executive Officer, Director
- Peter N. Kellogg, Chief Financial Officer, Executive Vice President
- Terrie Curran, President, Global Inflammation & Immunology Franchise
- Michael F. Pehl, President, Hematology & Oncology
- Rupert J. Vessey, President - Research and Early Development
- Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary
- Michael D. Casey, Lead Independent Director
- Michael W. Bonney, Director
Who owns Celgene Corporation stock?
Celgene Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.43%), Swedbank (0.33%), NN Investment Partners Holdings N.V. (0.15%), Strs Ohio (0.11%), KAMES CAPITAL plc (0.10%) and AMF Pensionsforsakring AB (0.10%). Company insiders that own Celgene Corporation stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin and Rupert Vessey. View Institutional Ownership Trends for Celgene Corporation.
Who sold Celgene Corporation stock? Who is selling Celgene Corporation stock?
Celgene Corporation's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Strs Ohio, Personal Capital Advisors Corp, Bedrijfstakpensioenfonds Voor DE Media PNO, PGGM Investments, Moody Lynn & Lieberson LLC, Exxonmobil Investment Management Inc. TX and Sumitomo Mitsui Asset Management Company LTD. Company insiders that have sold Celgene Corporation stock in the last year include Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin and Rupert Vessey. View Insider Buying and Selling for Celgene Corporation.
Who bought Celgene Corporation stock? Who is buying Celgene Corporation stock?
Celgene Corporation's stock was acquired by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., First Quadrant L P CA, Mn Services Vermogensbeheer B.V., Bank of Montreal Can, Hellman Jordan Management Co. Inc. MA, Fisher Asset Management LLC, OLD National Bancorp IN and Russell Investments Group Ltd.. Company insiders that have bought Celgene Corporation stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene Corporation.
How do I buy Celgene Corporation stock?
Shares of Celgene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celgene Corporation's stock price today?
MarketBeat Community Rating for Celgene Corporation (NASDAQ CELG)MarketBeat's community ratings are surveys of what our community members think about Celgene Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Celgene Corporation stock can currently be purchased for approximately $137.75.
Consensus Ratings for Celgene Corporation (NASDAQ:CELG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 5 Hold Ratings, 20 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.73)|
|Consensus Price Target: ||$141.27 (2.55% upside)|
Analysts' Ratings History for Celgene Corporation (NASDAQ:CELG)
(Data available from 7/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/21/2017||Robert W. Baird||Reiterated Rating||Outperform||$162.00||Low|
|7/14/2017||SunTrust Banks, Inc.||Reiterated Rating||Buy||$150.00||Low|
|7/11/2017||Jefferies Group LLC||Reiterated Rating||Buy -> Buy||$160.00||Low|
|7/10/2017||Bank of America Corporation||Reiterated Rating||Buy||$153.00||Low|
|7/6/2017||Credit Suisse Group||Set Price Target||Buy||$148.00||Low|
|7/6/2017||Stifel Nicolaus||Reiterated Rating||Buy||$139.00||Low|
|7/6/2017||Cantor Fitzgerald||Set Price Target||Buy||$160.00||Low|
|6/30/2017||BTIG Research||Downgrade||Buy -> Neutral||$96.93 -> $131.70||Low|
|6/26/2017||William Blair||Reiterated Rating||Outperform||Low|
|6/22/2017||Leerink Swann||Reiterated Rating||Outperform||Low|
|6/14/2017||Oppenheimer Holdings, Inc.||Set Price Target||Buy||$148.00||Low|
|6/6/2017||Canaccord Genuity||Set Price Target||Buy||$156.00||Low|
|6/1/2017||Mizuho||Boost Price Target||Buy -> Buy||$130.00 -> $134.00||Medium|
|5/24/2017||J P Morgan Chase & Co||Reiterated Rating||Buy||Low|
|5/23/2017||BMO Capital Markets||Reiterated Rating||Outperform||$152.00||Medium|
|5/17/2017||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Sell||$93.00 -> $98.00||Low|
|5/5/2017||Argus||Downgrade||Buy -> Hold||$123.91 -> $124.46||Medium|
|4/23/2017||Barclays PLC||Reiterated Rating||Equal Weight||$120.00 -> $125.00||Low|
|3/8/2017||Cowen and Company||Reiterated Rating||Outperform||$150.00||Low|
|1/27/2017||Morgan Stanley||Lower Price Target||Equal Weight||$120.00 -> $117.00||N/A|
|1/8/2017||Evercore ISI||Reiterated Rating||Buy||$135.00||N/A|
|12/4/2016||Royal Bank Of Canada||Reiterated Rating||Outperform||N/A|
|11/9/2016||Standpoint Research||Downgrade||Buy -> Hold||N/A|
|10/18/2016||Piper Jaffray Companies||Reiterated Rating||Buy||N/A|
|9/29/2016||Citigroup Inc.||Boost Price Target||Buy||$124.00 -> $127.00||N/A|
|7/6/2016||JMP Securities||Reiterated Rating||Buy||$152.00||N/A|
|4/28/2016||Raymond James Financial, Inc.||Reiterated Rating||Buy||N/A|
|1/22/2016||Wells Fargo & Company||Reiterated Rating||Outperform||N/A|
|12/18/2015||Atlantic Securities||Initiated Coverage||Neutral -> Neutral||N/A|
Earnings History for Celgene Corporation (NASDAQ:CELG)Earnings History by Quarter for Celgene Corporation (NASDAQ CELG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/27/2017||Q1 2017||$1.47||$1.68||$3.04 billion||$2.96 billion||View||N/A|
|1/26/2017||Q416||$1.59||$1.61||$3.03 billion||$2.98 billion||View||N/A|
|10/27/2016||Q316||$1.31||$1.58||$2.84 billion||$2.98 billion||View||Listen|
|7/28/2016||Q216||$1.39||$1.44||$2.70 billion||$2.74 billion||View||Listen|
|4/28/2016||Q116||$1.29||$1.32||$2.59 billion||$2.51 billion||View||Listen|
|1/28/2016||Q415||$1.22||$1.18||$2.54 billion||$2.54 billion||View||Listen|
|11/5/2015||Q315||$1.09||$1.23||$2.40 billion||$2.33 billion||View||N/A|
|7/23/2015||Q215||$1.08||$1.23||$2.24 billion||$2.28 billion||View||Listen|
|4/30/2015||Q115||$0.93||$0.95||$2.11 billion||$2.08 billion||View||N/A|
|1/29/2015||Q414||$0.88||$0.91||$2.08 billion||$2.09 billion||View||N/A|
|10/23/2014||Q314||$0.82||$0.97||$1.96 billion||$1.96 billion||View||Listen|
|7/24/2014||Q214||$0.77||$0.80||$1.85 billion||$1.87 billion||View||N/A|
|4/24/2014||Q114||$1.65||$1.67||$1.77 billion||$1.71 billion||View||N/A|
|1/30/2014||Q413||$1.54||$1.51||$1.72 billion||$1.76 billion||View||Listen|
|10/24/2013||Q313||$1.54||$1.56||$1.64 billion||$1.67 billion||View||N/A|
|7/25/2013||Q2 2013||$1.44||$1.52||$1.54 billion||$1.56 billion||View||Listen|
|4/25/2013||Q1 2013||$1.35||$1.37||$1.47 billion||$1.43 billion||View||Listen|
|1/24/2013||Q4 2012||$1.31||$1.32||$1.45 billion||$1.42 billion||View||Listen|
Earnings Estimates for Celgene Corporation (NASDAQ:CELG)
2017 EPS Consensus Estimate: $6.60
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Celgene Corporation (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Celgene Corporation (NASDAQ:CELG)
Insider Ownership Percentage: 0.95%Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Institutional Ownership Percentage: 78.39%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/26/2017||James J Loughlin||Director||Sell||18,500||$133.57||$2,471,045.00|| |
|6/22/2017||Michael A Friedman||Director||Sell||10,000||$132.50||$1,325,000.00|| |
|6/22/2017||Robert J Hugin||Insider||Sell||175,970||$134.14||$23,604,615.80|| |
|6/21/2017||Michael D Casey||Director||Sell||9,250||$133.05||$1,230,712.50|| |
|6/19/2017||Michael D. Casey||Director||Sell||9,250||$125.59||$1,161,707.50|| |
|6/15/2017||Rupert Vessey||Insider||Sell||4,785||$120.18||$575,061.30|| |
|5/1/2017||James J Loughlin||Director||Sell||9,250||$124.00||$1,147,000.00|| |
|3/30/2017||Gilla Kaplan||Director||Sell||14,033||$123.83||$1,737,706.39|| |
|3/1/2017||Rupert Vessey||Insider||Sell||4,000||$124.42||$497,680.00|| |
|11/9/2016||Michael A Friedman||Director||Sell||18,600||$116.10||$2,159,460.00|| |
|10/24/2016||Corp /De/ Celgene||Major Shareholder||Buy||800,150||$14.00||$11,202,100.00|| |
|10/3/2016||Michael A Friedman||Director||Sell||56,116||$103.66||$5,816,984.56|| |
|9/23/2016||Richard W Barker||Director||Sell||20,000||$110.82||$2,216,400.00|| |
|9/15/2016||Gilla Kaplan||Director||Sell||9,710||$106.44||$1,033,532.40|| |
|8/23/2016||James J Loughlin||Director||Sell||27,500||$114.10||$3,137,750.00|| |
|8/22/2016||Michael D Casey||Director||Sell||43,134||$114.01||$4,917,707.34|| |
|7/28/2016||Robert J Hugin||Insider||Sell||100,000||$110.00||$11,000,000.00|| |
|6/20/2016||Robert J Hugin||Insider||Sell||75,000||$100.16||$7,512,000.00|| |
|4/4/2016||Gilla Kaplan||Director||Sell||15,967||$101.84||$1,626,079.28|| |
|3/3/2016||Michael W Bonney||Director||Buy||2,000||$103.01||$206,020.00|| |
|2/22/2016||James J Loughlin||Director||Sell||2,100||$104.12||$218,652.00|| |
|12/28/2015||Ernest Mario||Director||Sell||40,000||$119.36||$4,774,400.00|| |
|12/23/2015||Michael D Casey||Director||Sell||20,000||$122.11||$2,442,200.00|| |
|12/21/2015||Gilla Kaplan||Director||Sell||14,464||$110.62||$1,600,007.68|| |
|9/10/2015||Gilla Kaplan||Director||Sell||15,000||$122.45||$1,836,750.00|| |
|9/8/2015||Michael D. Casey||Director||Sell||15,000||$121.76||$1,826,400.00|| |
|7/13/2015||Thomas O Daniel||Insider||Sell||30,156||$120.78||$3,642,241.68|| |
|6/10/2015||Gilla Kaplan||Director||Sell||15,000||$111.74||$1,676,100.00|| |
|6/9/2015||Michael D Casey||Director||Sell||15,000||$111.18||$1,667,700.00|| |
|2/26/2015||Gilla Kaplan||Director||Sell||15,000||$122.89||$1,843,350.00|| |
|2/6/2015||Mark J Alles||Insider||Sell||117,099||$120.68||$14,131,507.32|| |
|1/15/2015||Lawrence V Stein||Insider||Sell||26,666||$120.01||$3,200,186.66|| |
|1/2/2015||Gilla Kaplan||Director||Sell||45,536||$113.47||$5,166,969.92|| |
|12/8/2014||Gilla Kaplan||Director||Sell||15,000||$118.20||$1,773,000.00|| |
|11/3/2014||Robert J Hugin||Insider||Sell||158,000||$106.68||$16,855,440.00|| |
|10/27/2014||Ernest Mario||Director||Sell||100,000||$102.85||$10,285,000.00|| |
|10/24/2014||Michael D Casey||Director||Sell||15,000||$102.94||$1,544,100.00|| |
|9/8/2014||Gilla Kaplan||Director||Sell||30,000||$93.73||$2,811,900.00|| |
|8/4/2014||Perry A Karsen||Insider||Sell||39,104||$87.55||$3,423,555.20|| |
|7/25/2014||Richard W Barker||Director||Sell||17,600||$87.03||$1,531,728.00|| |
|5/1/2014||Perry Karsen||Insider||Sell||11,922||$146.78||$1,749,911.16|| |
|3/4/2014||Michael Casey||Director||Sell||12,770||$162.33||$2,072,954.10|| |
|2/5/2014||Ernest Mario||Director||Sell||13,500||$151.87||$2,050,245.00|| |
|12/23/2013||Lawrence Stein||Insider||Sell||12,062||$168.19||$2,028,707.78|| |
|10/25/2013||Carrie Smith Cox||Director||Sell||18,750||$157.67||$2,956,312.50|| |
|9/4/2013||Gilla Kaplan||Director||Sell||15,000||$143.92||$2,158,800.00|| |
|8/28/2013||Thomas Daniel||Insider||Sell||32,263||$137.06||$4,421,966.78|| |
|8/2/2013||Perry A Karsen||Insider||Sell||93,008||$146.50||$13,625,672.00|| |
|5/30/2013||Robert J Hugin||Insider||Sell||68,087||$123.58||$8,414,191.46|| |
|5/29/2013||Ernest Mario||Director||Buy||1,000||$123.72||$123,720.00|| |
|5/28/2013||Thomas O Daniel||Insider||Sell||32,959||$124.91||$4,116,908.69|| |
Headline Trends for Celgene Corporation (NASDAQ:CELG)
Latest Headlines for Celgene Corporation (NASDAQ:CELG)
Celgene Corporation (CELG) Chart for Wednesday, July, 26, 2017